DOCSLIB.ORG

ISTH Couverture 6.6.2012 10:21 Page 1 ISTH Couverture 6.6.2012 10:21 Page 2 ISTH Couverture 6.6.2012 10:21 Page 3 ISTH Couverture 6.6.2012 10:21 Page 4

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ISTH Couverture 6.6.2012 10:21 Page 1 ISTH Couverture 6.6.2012 10:21 Page 2 ISTH Couverture 6.6.2012 10:21 Page 3 ISTH Couverture 6.6.2012 10:21 Page 4 ISTH Couverture 6.6.2012 10:21 Page 1 ISTH Couverture 6.6.2012 10:21 Page 2 ISTH Couverture 6.6.2012 10:21 Page 3 ISTH Couverture 6.6.2012 10:21 Page 4 ISTH 2012 11.6.2012 14:46 Page 1 Table of Contents 3 Welcome Message from the Meeting President 3 Welcome Message from ISTH Council Chairman 4 Welcome Message from SSC Chairman 5 Committees 7 ISTH Future Meetings Calendar 8 Meeting Sponsors 9 Awards and Grants 2012 12 General Information 20 Programme at a Glance 21 Day by Day Scientific Schedule & Programme 22 Detailed Programme Tuesday, 26 June 2012 25 Detailed Programme Wednesday, 27 June 2012 33 Detailed Programme Thursday, 28 June 2012 44 Detailed Programme Friday, 29 June 2012 56 Detailed Programme Saturday, 30 June 2012 68 Hot Topics Schedule 71 ePoster Sessions 97 Sponsor & Exhibitor Profiles 110 Exhibition Floor Plan 111 Congress Centre Floor Plan www.isth.org ISTH 2012 11.6.2012 14:46 Page 2 ISTH 2012 11.6.2012 14:46 Page 3 WelcomeCommittees Messages Message from the ISTH SSC 2012 Message from the ISTH Meeting President Chairman of Council Messages Dear Colleagues and Friends, Dear Colleagues and Friends, We warmly welcome you to the elcome It is my distinct privilege to welcome W Scientific and Standardization Com- you to Liverpool for our 2012 SSC mittee (SSC) meeting of the Inter- meeting. national Society on Thrombosis and Dr. Cheng-Hock Toh and his col- Haemostasis (ISTH) at Liverpool’s leagues have set up a great Pro- UNESCO World Heritage Centre waterfront! gramme aiming at making our off-congress year As setting standards is fundamental to all quality meeting especially attractive for our participants. outcomes, our objective for this meeting in Liverpool Since 2008, beside the usual in-depth work of the will be to convey how the SSC is well-positioned to Subcommittees, our SSC meetings include a large translate new knowledge into better patient care. educational programme that targets young basic and Promoting cross-information exchange and engaging clinical scientists. Because of the smaller format of with external partners are key to deliver solutions for these meetings, compared to our biennial congresses, patients with haemostatic and thrombotic problems. it also allows to experiment with innovations. With a Developing future leaders is also key to the vitality of very encouraging number of abstracts submitted, we ISTH and this meeting will be rooted in the themes will have stimulating “hot topic abstracts” reporting of Education, Engagement and Translation.I am late-breaking results in basic and clinical science, and therefore delighted that SSC 2012 offers a coherent also regular abstracts featured as “e-posters”. These programme with a Trainees’ Day on Consultative Coagu- innovations will further foster the exchange of know- lation, an Education Day on Setting Standards of Care, ledge and the educational experience for our parti- a Presidential Plenary on Translational Thrombosis & cipants. Haemostasis and enhanced opportunities to Meet-the- I look forward to meeting you in the course of the week Experts. and attending and actively participating in what looks I look forward to greeting you personally and wish you like an outstanding program. the best of experiences in Liverpool ! Thank you for attending our 58th SSC meeting to With best wishes. experience the “science, culture, and friendship!”. Welcome to Liverpool ! CHENG-HOCK TOH HENRI BOUNAMEAUX M.D. M.D., FRCP, FRCPath 3 ISTH 2012 11.6.2012 14:46 Page 4 Welcome Messages Message from the SSC Chairman Dear Colleagues and Friends, Following the success of the SSC Professor Cheng-Hock Toh and his colleagues on the meeting in Kyoto, we are back in Local Organizing Committee have assembled a very Europe and I warmly welcome you to a high-level programme, which will also include for the new and very innovative meeting in first time “Hot topic abstracts” and regular abstracts Liverpool. that will be presented as e-posters. This novelty will As is the tradition of the SSC, the format of the 2012 help to highlight the most recent achievements in basic meeting is designed to favor an active exchange of new and clinical research and will be a great challenge for important information and topics of research, and to young investigators. stimulate cross-disciplinary collaborations. The confe- To maintain the high level reached by the SSC it is rence will start with a strong educational programme, important that those who are not currently a member, providing an opportunity of intensive training for our not only participate in the meeting, but make an active younger colleagues. Then the meetings of all sub- contribution, participating in the working projects and committees of the SSC will follow and the results of the registries, and become a member of one of the sub- new and on-going projects of each subcommittee will committees. be extensively discussed. This will provide the new The dynamic and energizing atmosphere of Liverpool insights into the most challenging practical issues in will provide the perfect setting for the offspring of new thrombosis and hemostasis, and also will grant an projects and collaborations, and will guarantee a great expert view on the standardization of basic and clinical success of the 2012 ISTH/SSC conference. research methods, nomenclature, preparation of Welcome to Liverpool ! reference reagents, and evaluation of new tests and new drugs. ANNA FALANGA M.D. 4 ISTH 2012 11.6.2012 14:46 Page 5 CommitteesCommittees Organizing Committee Factor VIII & Factor IX Flora Peyvandi (Italy) Cheng-Hock Toh, President (United Kingdom) Jecko Thachil (United Kingdom) Factor XI and the Contact System Simon Abrams (United Kingdom) Thomas Renne (Sweden) Tina Dutt (United Kingdom) Factor XIII and Fibrinogen Ian Greer (United Kingdom) Hans P Kohler (Switzerland) Colin Downey (United Kingdom) Fibrinolysis Officers of the Scientific and Standardization Ann Gils (Belgium) Committee Hemostasis & Malignancy Anna Falanga (Italy) Agnes Y Y Lee (Canada) Chairman (2010-2012) Lupus Anticoagulant/Phospholipid-dependent Committees David Lillicrap (Canada) Antibodies Secretary/Chairman-Elect (2010-2012 / 2012-2014) Thomas L Ortel (USA) Perinatal/Pediatric Hemostasis Subcommittees of the Scientific and Paul Monagle (Australia) Standardization Committee Animal, Cellular, and Molecular Models Plasma Coagulation Inhibitors of Thrombosis Steven Kitchen (United Kingdom) Susan S. Smyth (USA) Platelet Immunology Biorheology Yves Gruel (France) Michael R. King (USA) Platelet Physiology Control of Anticoagulation Paul Harrison (United Kingdom) Walter Ageno (Italy) Predictive Hemostatic Variables and Disseminated Intravascular Coagulation (DIC) Cardiovascular Disease Hideo Wada (Japan) James Douketis (Canada) Exogenous Hemostatic Factors, Registry of Jan Rosing (The Netherlands) 5 ISTH 2012 11.6.2012 14:46 Page 6 CommitteesCommittees Vascular Biology Class of 2014 Françoise Dignat-George (France) Nuala Booth (United Kingdom) Von Willebrand Factor Françoise Dignat-George (France) Jeroen CJ Eikenboom (The Netherlands) Nigel Key (USA) Robert Montgomery (USA) Women’s Health Issues in Thrombosis and Haemostasis Hugo ten Cate (The Netherlands) Sabine Eichinger (Austria) Class of 2016 SSC Working Group on Coagulation Standards Marco Cattaneo (Italy) Anthony Hubbard (United Kingdom) Björn Dahlbäck (Sweden) Andreas Greinacher (Germany) Council of the International Society on Paula Tracy (USA) Thrombosis and Haemostasis (ISTH) Yukio Ozaki (Japan) Chairman of Council (2010-2012) Henri Bounameaux (Switzerland) Ex-Officio Council Members Secretary/Chairman-Elect of Council Bruce Furie (USA) (2010-2012 / 2012-2014) Secretary General (2010-2014) Michael Berndt (Ireland) Frits R. Rosendaal (The Netherlands) Treasurer (2011-2015) President of the XXIV Congress (Amsterdam, 2013) & Immediate Past Chairman of Council Nuala Booth (United Kingdom) Class of 2012 Pieter Reitsma (The Netherlands) Vice-President of the XXIV (Amsterdam, 2013) Michael Berndt (Ireland) Congress Henri Bounameaux (Switzerland) Alan Nurden (France) Yasuo Ikeda (Japan) Bjarne Østerud (Norway) President of the XXIII Congress (Kyoto, 2011) Pieter Reitsma (The Netherlands) Mike Greaves and David Lane (United Kingdom) Editors-in-Chief, Journal of Thrombosis and Haemostasis Anna Falanga (Italy) Chairman, Scientific and Standardization Committee 6 ISTH 2012 11.6.2012 14:46 Page 7 Committees SSC 2012 Abstract Reviewers ISTH Future Meetings Calendar Ken Bauer (USA) XXIV ISTH Congress and 59th Annual SSC Meeting Nuala Booth (United Kingdom) Frits R. Rosendaal, President James Crawley (United Kingdom) Amsterdam, The Netherlands Françoise Dignat-George (France) 29 June - 4 July, 2013 Alison Goodall (United Kingdom) www.isth2013.com Tilman Hackeng (The Netherlands) Katherine Hajjar (USA) 60th Annual SSC Meeting Keith Hoots (USA) Robert R. Montgomery, President Bendt Jilma (Austria) Milwaukee, WI, USA Paul Kyrle (Austria) 2014 Nigel Mackman (USA) XXV ISTH Congress and 61st Annual SSC Meeting Committees Andrew Mumford (United Kingdom) XXV ISTH Congress and 61 Annual SSC Meeting Sam Schulman, President Bjarne Østerud (Norway) Toronto, Canada Evan Sadler (USA) 2015 Hugo ten Cate (The Netherlands) Jecko Thachil (United Kingdom) XXVI ISTH Congress and 63rd SSC Meeting Cheng-Hock Toh (United Kingdom) Johannes Oldenburg, President Theodore Warkentin (Canada) Berlin, Germany Steve Watson (United Kingdom) 2017 XXVII ISTH Congress and 65th SSC Meeting Robert Medcalf, President Melbourne, Australia 2019 7 ISTH 2012 11.6.2012 14:46 Page 8
Load more

Recommended publications
  • High Prevalence of Sticky Platelet Syndrome in Patients with Infertility and Pregnancy Loss
    Journal of Clinical Medicine Article High Prevalence of Sticky Platelet Syndrome in Patients with Infertility and Pregnancy Loss Eray Yagmur 1,* , Eva Bast 2, Anja Susanne Mühlfeld 3, Alexander Koch 4, Ralf Weiskirchen 5 , Frank Tacke 6 and Joseph Neulen 7 1 Medical Care Center, Dr. Stein and Colleagues, D-41169 Mönchengladbach, Germany 2 Department of Gynecology and Obstetrics, Bürgerhospital Frankfurt, D-60318 Frankfurt, Germany 3 Division of Nephrology and Clinical Immunology,RWTH-University Hospital Aachen, D-52074 Aachen, Germany 4 Department of Medicine III, RWTH-University Hospital Aachen, D-52074 Aachen, Germany 5 Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry, RWTH-University Hospital Aachen, D-52074 Aachen, Germany 6 Department of Hepatology and Gastroenterology,Charité University Medical Center, D-10117 Berlin, Germany 7 Department of Gynecological Endocrinology and Reproductive Medicine, RWTH-University Hospital Aachen, D-52074 Aachen, Germany * Correspondence: [email protected]; Tel.: +49-2161-8194-442 Received: 26 July 2019; Accepted: 26 August 2019; Published: 28 August 2019 Abstract: Platelet hyperaggregability, known as sticky platelet syndrome (SPS), is a prothrombotic disorder that has been increasingly associated with pregnancy loss. In this retrospective study, we aimed to investigate the clinical and diagnostic relevance of SPS in 208 patients with infertility and unexplained pregnancy loss history. We studied 208 patients that had been referred to undergo a dose-dependent platelet aggregation response to adenosine diphosphate and epinephrine using light transmission aggregometry modified by Mammen during an 11-year period. Patients’ platelet aggregation response was compared with platelet function in 29 female healthy controls of fertile age with no previous history of pregnancy loss.
    [Show full text]
  • The Rare Coagulation Disorders
    Treatment OF HEMOPHILIA April 2006 · No. 39 THE RARE COAGULATION DISORDERS Paula HB Bolton-Maggs Department of Haematology Manchester Royal Infirmary Manchester, United Kingdom Published by the World Federation of Hemophilia (WFH) © World Federation of Hemophilia, 2006 The WFH encourages redistribution of its publications for educational purposes by not-for-profit hemophilia organizations. In order to obtain permission to reprint, redistribute, or translate this publication, please contact the Communications Department at the address below. This publication is accessible from the World Federation of Hemophilia’s web site at www.wfh.org. Additional copies are also available from the WFH at: World Federation of Hemophilia 1425 René Lévesque Boulevard West, Suite 1010 Montréal, Québec H3G 1T7 CANADA Tel. : (514) 875-7944 Fax : (514) 875-8916 E-mail: [email protected] Internet: www.wfh.org The Treatment of Hemophilia series is intended to provide general information on the treatment and management of hemophilia. The World Federation of Hemophilia does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. Dose schedules and other treatment regimes are continually revised and new side effects recognized. WFH makes no representation, express or implied, that drug doses or other treatment recommendations in this publication are correct. For these reasons it is strongly recommended that individuals seek the advice of a medical adviser and/or to consult printed instructions provided by the pharmaceutical company before administering any of the drugs referred to in this monograph. Statements and opinions expressed here do not necessarily represent the opinions, policies, or recommendations of the World Federation of Hemophilia, its Executive Committee, or its staff.
    [Show full text]
  • Sticky Platelet Syndrome
    SEMINARS IN THROMBOSIS AND HEMOSTASIS—VOL. 25, NO. 4, 1999 Sticky Platelet Syndrome EBERHARD F. MAMMEN, M.D. ABSTRACT The sticky platelet syndrome (SPS) is an autosomal dominant platelet disorder associated with arterial and venous thromboembolic events. It is characterized by hyperaggregability of platelets in platelet-rich plasma with adenosine diphosphate (ADP) and epinephrine (type I), epinephrine alone (type II), or ADP alone (type III). Clinically, patients may present with angina pectoris, acute myocardial infarc• tion (MI), transient cerebral ischemic attacks, stroke, retinal thrombosis, peripheral arterial thrombosis, and venous thrombosis, frequently recurrent under oral anticoagulant therapy. Clinical symptoms, espe• cially arterial, often present following emotional stress. Combinations of SPS with other congenital throm- bophilic defects have been described. Low-dose aspirin treatment (80 to 100 mg) ameliorates the clinical symptoms and normalizes hyperaggregability. The precise etiology of this defect is at present not known, but receptors on the platelet surface may be involved. Normal levels of platelet factor 4 (PF4) and p-throm- boglobulin in plasma suggest that the platelets are not activated at all times; they appear to become hyper• active upon ADP or adrenaline release. In vivo clumping could temporarily or permanently occlude a ves• sel, leading to the described clinical manifestations. The syndrome appears to be prominent especially in patients with unexplained arterial vascular occlusions. Keywords: Platelets,
    [Show full text]
  • Study of Osmotic Fragility Status of Red Blood Cell in Type II Diabetes Mellitus Patients
    European Journal of Environment and Public Health, 2017, 1(2), 06 ISSN: 2468-1997 Study of Osmotic Fragility Status of Red Blood Cell in Type II Diabetes Mellitus Patients Nihad Rownak1, Shahin Akhter2, Monira Khatun3, Sohel Baksh4, Shafquat Rafiq5*, Mushfiqur Rahman6 1 Department of Physiology, University of Science & Technology Chittagong, BANGLADESH 2 Department of Physiology, Chittagong Medical College, Chittagong, BANGLADESH 3 Department of Physiology, Chattagram Maa O Shishu Hospital Medical College, Chittagong, BANGLADESH 4 Department of Physiology, Cox’s Bazar Medical College, BANGLADESH 5 Croydon University Hospital NHS Trust, UNITED KINGDOM 6 Department of Pediatric Surgery, Chittagong Medical College, Chittagong, BANGLADESH *Corresponding Author: [email protected] Citation: Rownak, N., Akhter, S., Khatun, M., Baksh, S., Rafiq, S., and Rahman, M. (2017). Study of Osmotic Fragility Status of Red Blood Cell in Type II Diabetes Mellitus Patients. European Journal of Environment and Public Health, 1(2), 06. https://doi.org/10.20897/ejeph/77094 Published: December 28, 2017 ABSTRACT Diabetes Mellitus (DM) is one of the most prevalent non-communicable diseases in the world. Cell membrane injury is an important mechanism for pathophysoilogical changes in DM. Osmotic fragility (OF) status of Red blood cell (RBC) in hyperglycemic patients is expected to be increased. This study was conducted in Chittagong medical college hospital and Chittagong Diabetic Hospital from January 2015 to December 2015. 100 newly diagnosed (duration ≤ 3 years) type II diabetes mellitus patients (Fasting blood glucose is ≥7 mmol/L) were selected as cases. Age, sex and BMI matched 100 healthy subjects were included as control. OF of RBC was measured by traditional method with a series of hypotonic solution of NaCl of different strength in twelve test tubes numbered serially.
    [Show full text]
  • 47 Effect of Gavage Treatment with Pulverised
    47 Nigerian Journal of Physiological Sciences 24 (1): 47-52 © Physiological Society of Nigeria, 2009 Available online/abstracted at http://www.biolineinternational.org.br/nps; www.ajol.info/journals.njps; www.cas.org EFFECT OF GAVAGE TREATMENT WITH PULVERISED GARCINIA KOLA SEEDS ON ERYTHROCYTE MEMBRANE INTEGRITY AND SELECTED HAEMATOLOGICAL INDICES IN MALE ALBINO WISTAR RATS A. A. AHUMIBE AND V. B. BRAIDE* Department of Pharmacology, Faculty of Basic Medical Science, College of Medical sciences, University of Calabar, PMB 1115, Calabar, Nigeria. E-mail: [email protected]. Tel.:+2348034048101 Summary: This study examines the effect of the whole seed of Garcinia kola (GKS ) on various blood parameters, in adult male albino rats. Five groups, of 6 animals per group, were treated by gavage with suspensions of graded concentrations of GKS daily for 5 weeks. The animals were then sacrificed and blood was obtained for estimation of the data herein presented. Packed red cell volume (PCV), hemoglobin concentration (Hb), and red blood cell count (RBC) showed significantly (P < 0.05, Student’s t-test) increased response to treatment with GKS; while the platelet and white blood cell (WBC) counts showed no corresponding increase with increasing GKS dosage. The mean red blood cell volume (MCV) and mean cell hemoglobin (MCH) levels decreased with increasing GKS dosage. Prothrombin time (PT) and activated partial thromboplastin time (APPT) were both prolonged with increased GKS dosage; while the serum lipids (cholesterol and triglycerides) decreased significantly (P< 0.05, Student’s t-test) with increased GKS dosage. Key Words: Garcinia kola; erythrocyte osmotic fragility; haematological parameters; serum cholesterol triglycerides Introduction One of many plant sources of therapeutic 2000); hypoglycaemic anti-diabetic activity (Iwu et ingredient among the people in West and Central al , 1990); bronchodilatation in man (Orie and Ekon Africa and some parts of Asia, is the seed plant 1993); antispasmodic effect on smooth muscle Garcinia kola Heckel (Guttiferae).
    [Show full text]
  • Controversies in Thrombosis and Hemostasis Part 2–Does Sticky Platelet Syndrome Exist?
    Published online: 2019-01-10 Commentary 69 Commentary: Controversies in Thrombosis and Hemostasis Part 2–Does Sticky Platelet Syndrome Exist? Emmanuel J. Favaloro, PhD, FFSc (RCPA)1 Giuseppe Lippi, MD2 1 Department of Haematology, Sydney Centres for Thrombosis and Address for correspondence Emmanuel J. Favaloro, PhD, FFSc (RCPA), Haemostasis, Institute of Clinical Pathology and Medical Research, Department of Haematology, Institute of Clinical Pathology and Westmead Hospital, Westmead, NSW, Australia Medical Research (ICPMR), Westmead Hospital, Westmead, NSW, 2 Section of Clinical Biochemistry, University of Verona, Verona, Italy Australia (e-mail: [email protected]). Semin Thromb Hemost 2019;45:69–72. Hemostasis ¼ love. plasma coagulation system (including clot formation).1 Although this provides a convenient separation to help teach Everyone talks about, but no one understands it. hemostasis to junior scientists, and to study this process in vitro, it needs to be recognized that, in vivo at least, these Hemostasis is complex. The process of hemostasis has sev- systems do not work in isolation. Primary and secondary eral outcomes, including physiologically arresting blood loss hemostasis work in concert to form the platelet plug. Injury at sites of vascular injury. In simple terms, this is achieved by to a blood vessel causes a cascade of events. The injury formation of a “plug that seals the hole.” This “plug” com- releases cellular components including “tissue factor,” as prises a framework of blood components that act together to well as exposing subendothelial surfaces that are normally create a stable mass that stops further blood leakage. not exposed to this blood. This causes activation of “second- Hemostasis involves the complex interaction of many ary hemostasis” by several mechanisms.
    [Show full text]
  • Whole-Exome Sequencing of a Patient with Severe and Complex Hemostatic Abnormalities Reveals a Possible Contributing Frameshift Mutation in C3AR1
    Downloaded from molecularcasestudies.cshlp.org on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press Whole-exome sequencing of a patient with severe and complex hemostatic abnormalities reveals a possible contributing frameshift mutation in C3AR1 Eva Leinøe1, Ove Juul Nielsen1, Lars Jønson2 and Maria Rossing2∗ Department of Hematology1 and Center for Genomic Medicine2, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark Running head: WES reveals a C3AR1 mutation in a complex hemostatic patient ∗Corresponding author: Maria Rossing Center for Genomic Medicine Rigshospitalet University of Copenhagen Blegdamsvej 9 DK-2100 Copenhagen Denmark E-mail: [email protected] Phone: +45 3545 3016 Fax: +45 3545 4435 1 Downloaded from molecularcasestudies.cshlp.org on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press Abstract The increasing availability of genome-wide analysis has made it possible to rapidly sequence the exome of patients with undiagnosed or unresolved medical conditions. Here, we present the case of a 64-year-old male patient with schistocytes in the peripheral blood smear and a complex and life-threatening coagulation disorder causing recurrent venous thromboembolic events, severe thrombocytopenia, and subdural hematomas. Whole-exome sequencing revealed a frameshift mutation (C3AR1 c.355-356dup, p.Asp119Alafs*19) resulting in a premature stop in C3AR1 (Complement Component 3a Receptor 1). Based on this finding, atypical hemolytic uremic syndrome was suspected due to a genetic predisposition, and a targeted treatment regime with Eculizumab was initiated. Life-threatening hemostatic abnormalities would most likely have persisted had it not been for the implementation of whole-exome sequencing in this particular clinical setting.
    [Show full text]
  • Diagnosis of Hemophilia and Other Bleeding Disorders
    Diagnosis of Hemophilia and Other Bleeding Disorders A LABORATORY MANUAL Second Edition Steve Kitchen Angus McCraw Marión Echenagucia Published by the World Federation of Hemophilia (WFH) © World Federation of Hemophilia, 2010 The WFH encourages redistribution of its publications for educational purposes by not-for-profit hemophilia organizations. For permission to reproduce or translate this document, please contact the Communications Department at the address below. This publication is accessible from the World Federation of Hemophilia’s website at www.wfh.org. Additional copies are also available from the WFH at: World Federation of Hemophilia 1425 René Lévesque Boulevard West, Suite 1010 Montréal, Québec H3G 1T7 CANADA Tel.: (514) 875-7944 Fax: (514) 875-8916 E-mail: [email protected] Internet: www.wfh.org Diagnosis of Hemophilia and Other Bleeding Disorders A LABORATORY MANUAL Second Edition (2010) Steve Kitchen Angus McCraw Marión Echenagucia WFH Laboratory WFH Laboratory (co-author, Automation) Training Specialist Training Specialist Banco Municipal Sheffield Haemophilia Katharine Dormandy de Sangre del D.C. and Thrombosis Centre Haemophilia Centre Universidad Central Royal Hallamshire and Thrombosis Unit de Venezuela Hospital The Royal Free Hospital Caracas, Venezuela Sheffield, U.K. London, U.K. on behalf of The WFH Laboratory Sciences Committee Chair (2010): Steve Kitchen, Sheffield, U.K. Deputy Chair: Sukesh Nair, Vellore, India This edition was reviewed by the following, who at the time of writing were members of the World Federation of Hemophilia Laboratory Sciences Committee: Mansoor Ahmed Clarence Lam Norma de Bosch Sukesh Nair Ampaiwan Chuansumrit Alison Street Marión Echenagucia Alok Srivastava Andreas Hillarp Some sections were also reviewed by members of the World Federation of Hemophilia von Willebrand Disease and Rare Bleeding Disorders Committee.
    [Show full text]
  • Approach to Bleeding Diathesi
    Approach to Bleeding Diathesis Dr.Nalini K Pati MD, DNB, DCH (Syd), FRCPA Paediatric Haematologist Royal Children’s Hospital Melbourne Australia Objectives Objectives - I I. Clinical aspects of bleeding Clinical aspects of bleeding II. Hematologic disorders causing bleeding • Coagulation factor disorders • Platelet disorders III. Approach to acquired bleeding disorders • Hemostasis in liver disease • Surgical patients • Warfarin toxicity IV. Approach to laboratory abnormalities • Diagnosis and management of thrombocytopenia V. Drugs and blood products used for bleeding Clinical Features of Bleeding Disorders Petechiae Platelet Coagulation (typical of platelet disorders) disorders factor disorders Site of bleeding Skin Deep in soft tissues Mucous membranes (joints, muscles) (epistaxis, gum, vaginal, GI tract) Petechiae Yes No Ecchymoses (“bruises”) Small, superficial Large, deep Hemarthrosis / muscle bleeding Extremely rare Common Do not blanch with pressure Bleeding after cuts & scratches Yes No (cf. angiomas) Bleeding after surgery or trauma Immediate, Delayed (1-2 days), usually mild often severe Not palpable (cf. vasculitis) Ecchymoses (typical of coagulation factor disorders) Objectives - II Hematologic disorders causing bleeding – Coagulation factor disorders – Platelet disorders Coagulation factor disorders Hemophilia A and B Inherited bleeding Acquired bleeding Hemophilia A Hemophilia B disorders disorders Coagulation factor deficiency Factor VIII Factor IX – Hemophilia A and B – Liver disease – vonWillebrands disease – Vitamin K Inheritance X-linked X-linked recessive recessive – Other factor deficiencies deficiency/warfarin overdose Incidence 1/10,000 males 1/50,000 males –DIC Severity Related to factor level <1% - Severe - spontaneous bleeding 1-5% - Moderate - bleeding with mild injury 5-25% - Mild - bleeding with surgery or trauma Complications Soft tissue bleeding Hemarthrosis (acute) Hemophilia Clinical manifestations (hemophilia A & B are indistinguishable) Hemarthrosis (most common) Fixed joints Soft tissue hematomas (e.
    [Show full text]
  • Åäãíàâëäàâ Êöéàéç 2017 Íóï 9
    ISSN 2074-9848 e-ISSN 2310-0532 ÅÄãíàâëäàâ êÖÉàéç 2017 íÓÏ 9 № 2 ä‡ÎËÌËÌ„ð‡‰ àÁ‰‡ÚÂθÒÚ‚Ó Å‡ÎÚËÈÒÍÓ„Ó Ù‰Âð‡Î¸ÌÓ„Ó ÛÌË‚ÂðÒËÚÂÚ‡ ËÏÂÌË àÏχÌÛË· ä‡ÌÚ‡ 2017 1 БАЛТИЙСКИЙ Редакционная коллегия РЕГИОН А. П. Клемешев, д-р полит. наук, проф., ректор БФУ им. И. Кан- та — главный редактор (Россия); Г. М. Федоров, д-р геогр. 2017 наук, проф., директор Института природопользования, терри- ториального развития и градостроительства, БФУ им. И. Кан- Том 9 та — зам. главного редактора (Россия); Й. фон Браун, дирек- тор Центра изучения развития, проф., Боннский университет № 2 (Германия); И. М. Бусыгина, д-р полит. наук, проф. кафедры сравнительной политологии, МГИМО (У) МИД РФ (Россия); Калининград : В. В. Воронов, д-р социол. наук, ведущий исследователь Инсти- тута социальных исследований, Даугавпилсский универси- Изд-во БФУ тет (Латвия); А. Г. Дружинин, д-р геогр. наук, директор Севе- им. И. Канта, 2017. ро-Кавказского научно-исследовательского института экономи- 185 с. ческих и социальный проблем, ЮФУ (Россия); М. В. Ильин, д-р полит. наук, проф. кафедры сравнительной политологии, Журнал основан МГИМО (У) МИД РФ (Россия); П. Йонниеми, старший науч- в 2009 году ный сотрудник, Карельский институт, Университет Восточ- ной Финляндии (Финляндия); Н. В. Каледин, канд. геогр. наук, Периодичность: доц., зав. каф. региональной политики и политической гео- графии, СПбГУ (Россия); В. А. Колосов, д-р геогр. наук, проф., 4 номера в год зав. лабораторией геополитических исследований, Институт на русском географии РАН (Россия); Г. В. Кретинин, д-р ист. наук, проф., и английском языках Институт гуманитарных наук, БФУ им. И. Канта (Россия); К. Люхто, проф., директор Пан-Европейского института выс- Учредители: шей школы экономики, Университет г.
    [Show full text]
  • Dysfibrinogenemia and Thrombosis
    Dys®brinogenemia and Thrombosis Timothy Hayes, DVM, MD c Objectives.ÐTo review the state of the art relating to sus of experts attending the conference was reached. The congenital dys®brinogenemia as a potential risk factor for results of the discussion were used to revise the manuscript thrombosis, as re¯ected by the medical literature and the into its ®nal form. consensus opinion of recognized experts in the ®eld, and Conclusions.ÐConsensus was reached on 5 conclusions to make recommendations for the use of laboratory assays and 2 recommendations concerning the use of testing for for assessing this thrombotic risk in individual patients. dys®brinogens in the assessment of thrombotic risk in in- Data Sources.ÐReview of the medical literature, pri- dividual patients. Detailed discussion of the rationale for marily from the last 10 years. each of these recommendations is found in the text of this Data Extraction and Synthesis.ÐAfter an initial assess- article. Compared with the other, more common heredi- ment of the literature, key points were identi®ed. Experts tary thrombophilias, dys®brinogenemia encompasses a di- were assigned to do an in-depth review of the literature verse group of defects with varied clinical expressions. and to prepare a summary of their ®ndings and recom- Congenital dys®brinogenemia is a relatively rare cause of mendations. A draft manuscript was prepared and circu- thrombophilia. Therefore, routine testing for this disorder lated to every participant in the College of American Pa- is not recommended as part of the laboratory evaluation thologists Conference on Diagnostic Issues in Thrombo- of a thrombophilic patient.
    [Show full text]
  • Final Program N
    XXII Congress The International Society on Thrombosis and Haemostasis B July 11-16 2009 O 55th Annual Meeting S of the Scientific and Standardization Committee of the ISTH T O Final Program N Boston - July 11-16 2009 XXII Congress of the International Society on Thrombosis and Haemostasis 2009 Table ISTH of Contents Venue and Contacts 2 Wednesday 209 Welcome Messages 3 – Plenary Lectures 210 Committees 7 – State of the Art Lectures 210 Congress Awards and Grants 15 – Abstract Symposia Lectures 212 Other Meetings 19 – Oral Communications 219 – Posters 239 ISTH Information 20 Program Overview 21 Thursday 305 SSC Meetings and – Plenary Lectures 306 Educational Sessions 43 – State of the Art Lectures 306 – Abstract Symposia Lectures 309 Scientific Program 89 – Oral Communications 316 Monday 90 – Posters 331 – Plenary Lectures 90 Nursing Program 383 – State of the Art Lectures 90 Special Symposia 389 – Abstract Symposia Lectures 92 Satellite Symposia 401 – Oral Communications 100 – Posters 118 Technical Symposia Sessions 411 Exhibition and Sponsors 415 Tuesday 185 – Plenary Lectures 186 Exhibitor and Sponsor Profiles 423 – State of the Art Lectures 186 Congress Information 445 – Abstract Symposia Lectures 188 Map of BCEC 446 – Oral Communications 196 Hotel and Transportation Information 447 ISTH 2009 Congress Information 452 Boston Information 458 Social Events 463 Excursions 465 Authors’ Index 477 1 Venue & Contacts Venue Boston Convention & Exhibition Center 415 Summer Street - Boston, Massachusetts 02210 - USA Phone: +1 617 954 2800 - Fax: +1 617 954 3326 The BCEC is only about 10 minutes by taxi from Boston Logan International Airport. The 2009 Exhibition is located in Hall A and B of the Exhibit Level of the BCEC, along with posters and catering.
    [Show full text]